AstraZeneca has recorded total revenue growth in all geographic regions in its full-year results.

The pharmaceutical firm reported an 8% increase in its total revenue, which reached $58.7bn in the year to 31 December. This figure was driven by performances in its oncology, CVRM, R&I and rare disease divisions.

Furthermore, its profit before tax increased by 43% to $12.4bn in this period, while its core earnings per share jumped by 11% to $9.16.

The latest update comes after AstraZeneca saw a strong commercial performance in its therapy areas, after announcing the results of 16 positive Phase 3 studies throughout the year.

As a result, it now has 16 "blockbuster" medicines, it said, with 43 approvals in major regions in the past year.

Chief executive officer at AstraZeneca, Pascal Soriot, said: "The momentum across our company is continuing in 2026 and we are looking forward to the results of more than 20 Phase 3 trial readouts this year. We have more than 100 Phase 3 studies ongoing, including a substantial and growing number of trials of our transformative technologies which have the potential to revolutionise outcomes for patients and drive our growth well beyond 2030.

"Lastly, ordinary shares in our company began trading on the NYSE on 2 February, resulting in a harmonised listing structure across exchanges in London, New York and Stockholm, enabling more shareholders to participate in our company's exciting future."

In its outlook, AstraZeneca said it expects total revenue to increase by a mid-to-high single-digit percentage, while its core earnings per share is set to rise by a low double-digit percentage.

Following the publication of its final results, shares in the pharmaceutical firm jumped by 3%.

Investment director at AJ Bell, Russ Mould, stated that there is a lot going right for AstraZeneca.

He concluded: "Existing products are selling well, there is positive news on drug trials, it continues to make strategic acquisitions and partnerships, and the share price is humming along nicely.

"All big pharma companies strive to have a vibrant pipeline of drugs in development as these are the key to tomorrow’s revenue growth. AstraZeneca has an important year ahead with more than 20 final-phase trial results scheduled.

"It’s rare for a company to get a positive result with every single trial, so the goal is to have more successes than failures. If AstraZeneca knocks it out of the park with its current pipeline of final-stage trials, it could stand head and shoulders above the peer group."

---